|
1
|
Llovet JM, Kelley RK, Villanueva A, Singal
AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and
Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Singal AG, Lampertico P and Nahon P:
Epidemiology and surveillance for hepatocellular carcinoma: New
trends. J Hepatol. 72:250–261. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Park JW, Chen M, Colombo M, Roberts LR,
Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS and
Sherman M: Global patterns of hepatocellular carcinoma management
from diagnosis to death: The BRIDGE Study. Liver Int. 35:2155–2166.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Giraud J, Chalopin D, Blanc JF and Saleh
M: Hepatocellular carcinoma immune landscape and the potential of
immunotherapies. Front Immunol. 12:6556972021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Llovet JM, De Baere T, Kulik L, Haber PK,
Greten TF, Meyer T and Lencioni R: Locoregional therapies in the
era of molecular and immune treatments for hepatocellular
carcinoma. Nat Rev Gastroenterol Hepatol. 18:293–313. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
O'Neill TJ, Tofaute MJ and Krappmann D:
Function and targeting of MALT1 paracaspase in cancer. Cancer Treat
Rev. 117:1025682023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gomez Solsona B, Schmitt A,
Schulze-Osthoff K and Hailfinger S: The Paracaspase MALT1 in
Cancer. Biomedicines. 10:3442022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tsui KH, Chang KS, Sung HC, Hsu SY, Lin
YH, Hou CP, Yang PS, Chen CL, Feng TH and Juang HH:
Mucosa-Associated lymphoid tissue 1 is an oncogene inducing cell
proliferation, invasion, and tumor growth via the upregulation of
NF-κB activity in human prostate carcinoma cells. Biomedicines.
9:2502021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheng L, Deng N, Yang N, Zhao X and Lin X:
Malt1 protease is critical in maintaining function of regulatory T
cells and may be a therapeutic target for antitumor immunity. J
Immunol. 202:3008–3019. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mazi FA, Cakiroglu E, Uysal M, Kalyoncu M,
Demirci D, Sozeri PYG, Yilmaz GO, Ozhan SE and Senturk S: The
paracaspase MALT1 is a downstream target of Smad3 and potentiates
the crosstalk between TGF-β and NF-kB signaling pathways in cancer
cells. Cell Signal. 105:1106112023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rosenbaum M, Gewies A, Pechloff K, Heuser
C, Engleitner T, Gehring T, Hartjes L, Krebs S, Krappmann D,
Kriegsmann M, et al: Bcl10-controlled Malt1 paracaspase activity is
key for the immune suppressive function of regulatory T cells. Nat
Commun. 10:23522019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Di Pilato M, Kim EY, Cadilha BL, Prussmann
JN, Nasrallah MN, Seruggia D, Usmani SM, Misale S, Zappulli V,
Carrizosa E, et al: Targeting the CBM complex causes T(reg) cells
to prime tumours for immune checkpoint therapy. Nature.
570:112–116. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu Z, Liu X, Liang J, Liu Y, Hou X, Zhang
M, Li Y and Jiang X: Immunotherapy for Hepatocellular Carcinoma:
Current Status and Future Prospects. Front Immunol. 12:7651012021.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang C, Zhang H, Zhang L, Zhu AX, Bernards
R, Qin W and Wang C: Evolving therapeutic landscape of advanced
hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol.
20:203–222. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Finn RS, Ryoo BY, Merle P, Kudo M,
Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, et
al: Pembrolizumab as second-line therapy in patients with advanced
hepatocellular carcinoma in KEYNOTE-240: A Randomized,
double-blind, phase III trial. J Clin Oncol. 38:193–202. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux
M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab
plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J
Med. 382:1894–1905. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Llovet JM, Pinyol R, Kelley RK,
El-Khoueiry A, Reeves HL, Wang XW, Gores GJ and Villanueva A:
Molecular pathogenesis and systemic therapies for hepatocellular
carcinoma. Nat Cancer. 3:386–401. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Llovet JM, Brú C and Bruix J: Prognosis of
hepatocellular carcinoma: The BCLC staging classification. Semin
Liver Dis. 19:329–338. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou J, Sun H, Wang Z, Cong W, Wang J,
Zeng M, Zhou W, Bie P, Liu L, Wen T, et al: Guidelines for the
diagnosis and treatment of hepatocellular carcinoma (2019 Edition).
Liver Cancer. 9:682–720. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pugh RN, Murray-Lyon IM, Dawson JL,
Pietroni MC and Williams R: Transection of the oesophagus for
bleeding oesophageal varices. Br J Surg. 60:646–649. 1973.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schwartz LH, Litiere S, de Vries E, Ford
R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J,
et al: RECIST 1.1-Update and clarification: From the RECIST
committee. Eur J Cancer. 62:132–137. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen X, Zhang X, Lan L, Xu G, Li Y and
Huang S: MALT1 positively correlates with Th1 cells, Th17 cells,
and their secreted cytokines and also relates to disease risk,
severity, and prognosis of acute ischemic stroke. J Clin Lab Anal.
35:e239032021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xia Y, Tang W, Qian X, Li X, Cheng F, Wang
K, Zhang F, Zhang C, Li D, Song J, et al: Efficacy and safety of
camrelizumab plus apatinib during the perioperative period in
resectable hepatocellular carcinoma: A single-arm, open label,
phase II clinical trial. J Immunother Cancer. 10:e0046562022.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Finn RS, Ikeda M, Zhu AX, Sung MW, Baron
AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, et al:
Phase Ib study of lenvatinib plus pembrolizumab in patients with
unresectable hepatocellular carcinoma. J Clin Oncol. 38:2960–2970.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ning S, Li X, Ma X, Liu J and Chang X:
Efficacy of TACE combined with lenvatinib plus sintilimab for
hepatocellular carcinoma with tumor thrombus in the inferior vena
cava and/or right atrium. J Hepatocell Carcinoma. 10:1511–1525.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu Q, Wang Y, Ungchusri E, Patel M, Kumari
D, Van Ha T, Pillai A, Liao CY and Ahmed O: Combination of
transarterial radioembolization with atezolizumab and bevacizumab
for intermediate and advanced staged hepatocellular carcinoma: A
preliminary report of safety and feasibility. J Interv Med.
6:187–193. 2023.PubMed/NCBI
|
|
29
|
Chen J, Hu X, Li Q, Dai W, Cheng X, Huang
W, Yu W, Chen M, Guo Y and Yuan G: Effectiveness and safety of
toripalimab, camrelizumab, and sintilimab in a real-world cohort of
hepatitis B virus associated hepatocellular carcinoma patients. Ann
Transl Med. 8:11872020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ren Y, Liu Z, Makamure J, Kan X, Song S,
Liu Y, Qian K, Zheng C and Liang B: Addition of camrelizumab to
transarterial chemoembolization in hepatocellular carcinoma with
untreatable progression. Technol Cancer Res Treat.
21:153303382211313852022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang L, Gong JF, Pan HM, Bai YX, Liu TS,
Cheng Y, Chen YC, Huang JY, Xu TT, Ge FJ, et al: Atezolizumab
therapy in Chinese patients with locally advanced or metastatic
solid tumors: An open-label, phase I study. Beijing Da Xue Xue Bao
Yi Xue Ban. 54:971–980. 2022.(In Chinese). PubMed/NCBI
|
|
32
|
El-Khoueiry AB, Trojan J, Meyer T, Yau T,
Melero I, Kudo M, Hsu C, Kim TY, Choo SP, Kang YK, et al: Nivolumab
in sorafenib-naive and sorafenib-experienced patients with advanced
hepatocellular carcinoma: 5-year follow-up from CheckMate 040. Ann
Oncol. 35:381–391. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shen W, Du R, Li J, Luo X, Zhao S, Chang
A, Zhou W, Gao R, Luo D, Wang J, et al: TIFA suppresses
hepatocellular carcinoma progression via MALT1-dependent and
-independent signaling pathways. Signal Transduct Target Ther.
1:160132016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kurden-Pekmezci A, Cakiroglu E, Eris S,
Mazi FA, Coskun-Deniz OS, Dalgic E, Oz O and Senturk S: MALT1
paracaspase is overexpressed in hepatocellular carcinoma and
promotes cancer cell survival and growth. Life Sci. 323:1216902023.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hu X, Chen R, Wei Q and Xu X: The
landscape of alpha fetoprotein in hepatocellular carcinoma: Where
are we? Int J Biol Sci. 18:536–551. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zheng Y, Zhu M and Li M: Effects of
alpha-fetoprotein on the occurrence and progression of
hepatocellular carcinoma. J Cancer Res Clin Oncol. 146:2439–2446.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Frizinsky S, Rechavi E, Barel O, Najeeb
RH, Greenberger S, Lee YN, Simon AJ, Lev A, Ma CA, Sun G, et al:
Novel MALT1 mutation linked to immunodeficiency, immune
dysregulation, and an abnormal T cell receptor repertoire. J Clin
Immunol. 39:401–413. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang N, Ji F, Cheng L, Lu J, Sun X, Lin X
and Lan X: Knockout of immunotherapy prognostic marker genes
eliminates the effect of the anti-PD-1 treatment. NPJ Precis Oncol.
5:372021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Baens M, Stirparo R, Lampi Y, Verbeke D,
Vandepoel R, Cools J, Marynen P, de Bock CE and Bornschein S: Malt1
self-cleavage is critical for regulatory T cell homeostasis and
anti-tumor immunity in mice. Eur J Immunol. 48:1728–1738. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Magen A, Hamon P, Fiaschi N, Soong BY,
Park MD, Mattiuz R, Humblin E, Troncoso L, D'Souza D, Dawson T, et
al: Intratumoral dendritic cell-CD4(+) T helper cell niches enable
CD8(+) T cell differentiation following PD-1 blockade in
hepatocellular carcinoma. Nat Med. 29:1389–1399. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Barsch M, Salie H, Schlaak AE, Zhang Z,
Hess M, Mayer LS, Tauber C, Otto-Mora P, Ohtani T, Nilsson T, et
al: T-cell exhaustion and residency dynamics inform clinical
outcomes in hepatocellular carcinoma. J Hepatol. 77:397–409. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang H, Jiang Z and Zhang L: Dual effect
of T helper cell 17 (Th17) and regulatory T cell (Treg) in liver
pathological process: From occurrence to end stage of disease. Int
Immunopharmacol. 69:50–59. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zheng X, Jin W, Wang S and Ding H:
Progression on the roles and mechanisms of tumor-infiltrating T
lymphocytes in patients with hepatocellular carcinoma. Front
Immunol. 12:7297052021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lainé A, Labiad O, Hernandez-Vargas H,
This S, Sanlaville A, Léon S, Dalle S, Sheppard D, Travis MA,
Paidassi H and Marie JC: Regulatory T cells promote cancer
immune-escape through integrin αvβ8-mediated TGF-β activation. Nat
Commun. 12:62282021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li Q, He J, Li S, Tian C, Yang J, Yuan H,
Lu Y, Fagone P, Nicoletti F and Xiang M: The combination of
gemcitabine and ginsenoside Rh2 enhances the immune function of
dendritic cells against pancreatic cancer via the
CARD9-BCL10-MALT1/NF-κB pathway. Clin Immunol. 248:1092172023.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hayashi H, Chiba T, Mihara-Tomiyama N,
Negishi T, Kodama Y, Sakashita H and Imai K: Domain structures of
mucosa-associated lymphoid tissue lymphoma translocation 1 protein
for nuclear localization in oral carcinoma cells and the
proliferation inhibition. Biochem Biophys Res Commun. 522:799–804.
2020. View Article : Google Scholar : PubMed/NCBI
|
